








key: cord-324908-ptlpsnfo
authors: Cao, Huiling; Shi, Yuan
title: Convalescent plasma: possible therapy for novel coronavirus disease 2019
date: 2020-05-02
journal: Transfusion
DOI: 10.1111/trf.15797
sha: 
doc_id: 324908
cord_uid: ptlpsnfo

nan

T he recent coronavirus disease 2019 (COVID- 19) epidemic is spreading all over the world. By March 23, over 300,000 patients had been confirmed and almost 15,000 died because of COVID-19. More than 200,000 cases have been confirmed in other countries and regions outside China. Italy is the worst affected country in Europe. So far, no specific effective treatment has been developed for COVID-19 except for meticulous supportive care including critical care and organ support when necessary. Convalescent plasma might be a potential treatment for COVID-19. 1 Convalescent plasma refers to a plasma therapy based on plasma or plasma derivatives obtained from donors who have survived previous infections by developing antibodies and infusing into newly infected individuals. 2 The precise action mechanism of convalescent plasma therapy is not fully stated. There are some assumptions: First and foremost, the assumption is that convalescent plasma contains protective antibodies by neutralizing the pathogen, eventually leading to its eradication from the blood circulation. Rapid viral clearance would prevent further replication and the stimulus for the cytokine cascade. The level of anti-Ebola virus immunoglobulin G (IgG) titers was found to be associated with a delay in the peak of viral replication in a lethal Ebola virus-infected mouse model. 3 Another assumption is that convalescent plasma can convey other healing factors, such as preventing excess vascular leakage, procoagulant or antifibrinolytic factors, restoring the endothelium glycocalyx. 2, 4 Convalescent plasma plays an important role as one of the treatments for many viral infections when vaccines or other specific treatments are not available.

Convalescent plasma has been applied more than 100 years (the first well documented was the Spanish flu in 1917-1919). 2 There is an urgent need to have protective measures for nonexposed populations, prophylaxis for exposed but not yet infected populations, and experimental therapy for attacked individuals. [5] [6] [7] [8] [9] [10] [11] [12] Each of those situations including the early Spanish flu have proposed the use of convalescent plasma therapy. Evidence shows that it is also effective in infectious diseases such as Lassa fever, 13 Argentine hemorrhagic fever, 14 measles, 15 and Sin Nombre virus. 16 Public Health of England and the International Severe Acute Respiratory and Emerging Infection Consortium 17 put forward that convalescent plasma could be a promising specific treatment for serious Middle East respiratory syndrome (MERS), and further evaluation is needed in human clinical trials. 18 The World Health Organization (WHO) announced in September 2014 that serum from people who are convalescing from infection with the Ebola virus can be used to treat new patients. 19 twice tested negative for Ebola virus RNA by molecular techniques (the two samples for Ebola virus RNA testing  should be taken at least 48 hours apart, and the test results  should be negative on each sample) , and aged between 18 years old and 55 years old, could be considered as potential convalescent plasma donors. A dosage of 400 to 500 mL of convalescent plasma was given in two doses of 200 to 250 mL each, separated from two different whole blood donations. For pediatric convalescent plasma transfusion, a dose of 10 mL/kg could be used based on the considerations of blood volume. Donors needed to be seronegative of HIV, hepatitis B virus, hepatitis C virus, syphilis, and other locally transmitted infections. 19 

Convalescent plasma has been used to treat several viral infections, including SARS, avian influenza A (H5N1), influenza A (H1N1), MERS, and Ebola virus. Although many studies have reported the efficacy and safety of convalescent plasma infusion in the treatment of various infections, due to the lack of large-scale, randomized, well-designed, and prospective clinical trials, we tend to consider convalescent plasma as an "empirical" therapy. 20 Many studies have shown that convalescent plasma can effectively reduce viral load and increase antibodies to inhibit virus replication. Nevertheless, subsequent trials about convalescent plasma showed different results. 13 The characteristics of primary study are described in Table 1 . See Table S1 (available as supporting information in the online version of this paper) for detailed data (https://data.mendeley. com/datasets/n8w9n7rgz3/1).

A retrospective comparative study showed a shorter hospital stay after convalescent plasma therapy in SARS patients who deteriorated despite ribavirin and high-dose steroid therapy (74% vs. 19%; p = 0.001). Compared with five people who died in the continuing high-dose methylprednisolone group, there were no deaths in the plasma group (p = 0.049). 6 A case report by Wong et al. 21 stated that a 57-year-old woman infected with SARS improved gradually in clinical signs and symptoms after receiving a single 200-mL dose of convalescent plasma by 15 days after symptoms onset, suggesting that convalescent plasma combined with antiviral drugs and a corticosteroid may be an available option for the treatment of SARS infection. 21 A study reported recovery of three patients infected with SARS who developed severe progression and failed to respond to the ribavirin or methylprednisone. The study shows that viral load dropped from 495 × 10 3 , 76 × 10 3 , or 65 × 010 3 copies/ mL to zero or one copy/mL 1 day after transfusion, and anti-SARS-Cov immunoglobulin M (IgM) and IgG also increased in a time-dependent manner following convalescent plasma transfusion. 22

Two cases of convalescent plasma were reported. Both showed absolute reductions in viral load. One shows that the H7N9 virus was undetectable, the number of lymphocytes had been normalized by 4 days after infusing 200 mL of convalescent plasma with a titer of 80, and a computed tomography scan of the consolidation in the left lung had improved markedly after 12 days. 23 Another case report provided by Zhou et al., found that the virus load was reduced from 1.68 × 105 to 1.42 × 104 copies per milliliter during the first 8 hours and was undetectable within 32 hours after infusing convalescent plasma. 9 A look-back study suggests that patients with Spanish influenza pneumonia who received transfusion with influenza-convalescent human blood products may have experienced a clinical reduction in the risk of death. The overall crude case fatality rate was 16% (54/336) among treated patients and 37% (452/1219) among controls. A significant absolute reduction in the case fatality rate was observed in the patients treated within 4 days (19%; 28/) compared with 4 days or later (59%; 49/83). Therefore early definitive therapy is of great significance for pneumonia and hypoxia. 24 In 2012, Rockman et al. 8 conducted an animal experiment in which ferrets were exposed to lethal doses of highly pathogenic influenza H5N1, infused with hyperimmune serum at three different times (24 hr before or 24 hr after virus exposure at the onset of fever [>40°C] or immediately before the earliest expected onset of significant clinical signs [estimated from previous studies as Day 3 after exposure]). A total of 12 ferrets were included in the treatment group. The purpose of this study was to investigate the effects of convalescent plasma infusion at different time periods on survival. All four animals transfused hyperimmune serum 24 hours before virus exposure survived and were generally well, with slight weight loss. We can conclude that the greatest benefit was derived from passive immunization provided immediately before contact with an infectious dose of virus, compared to buffer controls or H3N2 nonhomologous hyperimmune serum. A prospective cohort study designed by Hung et al. 25 in which patients received a single 500-mL dose of convalescent plasma with an antibody titer greater than 160. Mortality in the treatment group was significantly lower than in the nontreatment group ( controlled trial reported that patients who received immune plasma and standard care for severe influenza showed a nonsignificant reduction in the mortality rate. 26 

In 1995, a small study reported that eight patients received 150 to 400 mL of convalescent plasma and seven survived, for a case fatality rate of 12.5% in comparison to 80% in patients without convalescent plasma treatment. 29 However, van Griensven et al. 4 performed a nonrandomized comparison study in which patients received two consecutive transfusions of 200 mL to 250 mL with unknown levels of antibody titer. Eighty-four patients received convalescent plasma was not associated with a significant improvement in survival. From Day 3 to Day 16 after diagnosis, the risk of death was 31% (26/84 patients) in the convalescent plasma group and 38% (158/418 patients) in the control group (risk difference, −7 percentage points; 95% CI, −18 to 4). In conclusion, the transfusion of up to 500 mL of convalescent plasma with unknown levels of neutralizing antibodies in 84 patients with confirmed Ebola virus infection was not associated with a significant improvement in survival. Further clinical trial is worth performing.

COVID-19 belongs to the same coronavirus family as SARS and MERS. Many life-threatening complications, such as acute respiratory distress syndrome, can occur during the viral mass replication phase. None of them had specific and effective treatment. According to previous studies and WHO recommendations, convalescent plasma might be used when a specific treatment is not available. According to the press conference of the Joint Prevention and Control Mechanism of the State Council on February 28 (Guangming Net of China), up to 544 doses of plasma from convalescent COVID-19 patients have been collected across the country and applied to 245 COVID-19 patients. Of the 157 COVID-19 patients who received convalescent plasma therapy and were closely monitored for more than 48 hours, 91 cases showed improvement in clinical indicators and symptoms.

The plasma therapy has proved to be safe and effective. Neutralizing antibodies against the novel coronavirus have been identified in the plasma of convalescent patients. A pilot study that has just been reported shows that the convalescent plasma (titer ≥ 640) therapy was safe and could improve clinical symptoms and laboratory parameters. 30 We look forward to the release of relevant data about convalescent plasma applied in COVID-19. More prospective comparative studies are needed to confirm the efficacy of convalescent plasma.

No serious adverse events were associated with convalescent plasma treatment. 4, 5, 31 The most commonly reported mild adverse event was a brief "chill" reaction with a transient hyperpyrexia after the convalescent plasma transfusion. Few patients develop transfusion-related adverse events such as phlebitis, generalized jaundice, or anaphylaxis. 24 A case report raised an association between transfusion-related acute lung injury and convalescent plasma. 32

In most viral illnesses, viremia peaks in the first week of infection. The patient then develops a primary immune response by Day 10 to Day 14, followed by virus clearance. Arabi et al. 18 studied the time course of specific antibody response and found that those antibodies peaked 1 week after the inoculation and then began declining. Therefore, convalescent plasma should be more effective when given early during the course of infections. SARS patients whose clinical condition deteriorated after receiving ribavirin and methylprednisolone had a higher discharge rate by Day 22, a shorter hospital stay, and a lower mortality rate when convalescent plasma was administered before Day14 of illness onset. 5 In a study of patients with Lassa fever in Nigeria, all eight patients who received convalescent plasma before Day 10 of illness recovered and survived, while only three of eight patients who received plasma after Day 10 survived. 13 the first 3 weeks of symptom onset, there was an increase in the titer of IgG and IgM antibodies to SARS-CoV-2. All those patients achieved a seroconversion of IgG or IgM within 20 days after symptom onset. The median day of seroconversion for both IgG and IgM was 13 days (after symptoms onset). The IgG levels in all the patients reached the platform in 6 days after the first positive points. It means that we should use convalescent plasma within 3 weeks after symptoms onset. 33 These findings suggest that early initiation of convalescent plasma treatment may be of critical importance to reduce mortality in patients with SARS or other pathogen infection. 31 However, a report showed that, when convalescent plasma transfusions were initiated on the day of diagnosis or up to 2 days later, the risk of death on Day 3 to Day 16 was nonsignificant. 4 Therefore, whether earlier use of convalescent plasma is better need more evidences.

There are still some issues to consider in determining the advisability of implementing a large-scale convalescent plasma transfusion program: What is the optimal timing for infusion? How long after clinical resolution of symptoms is there a chance to obtain neutralization antibodies if any? What is the most effective frequency of administration of convalescent plasma? Is clinical therapeutic effect related to antibody titer? Is it more likely to benefit young children and pregnant women? How do we make efficient use of convalescent plasma? More physiological studies are needed to explore why convalescent plasma is superior to fresh plasma and convalescent whole blood. Clinical research needs to explore the relationship between time (both extraction time and infusion time), volume, frequency, antibody titer and other healing factors, and clinical symptoms and signs of the patient. There is limited availability of eligible potential donors with sufficient levels of antibody. More large-scale, randomized, well-designed prospective studies are needed. Of note, eight studies, including a randomized controlled trial, have been registered in the Chinese Clinical Trial Registry (http://www.chictr.org.cn), preparing for clinical research (ChiCTR2000030690, ChiCTR2000030627, ChiCTR2000030557, ChiCTR2000030381, ChiCTR2000030312, ChiCTR2000030046, ChiCTR2000030039, ChiCTR2000029850).

Convalescent plasma is now used as an empirical treatment in the absence of specific treatment for COVID-19 and other dangerous viral infections, although its efficacy remains controversial. There are still some questions need to be explored. We look forward to more well-designed prospective studies.

HC drafted the initial manuscript and reviewed the manuscript.

YS critically reviewed the manuscript for important intellectual content. This work is attributed to Children's Hospital of Chongqing Medical University.

Convalescent plasma as a potential therapy for COVID-19

Use of convalescent plasma in Ebola virus infection

Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication

Evaluation of convalescent plasma for Ebola virus disease in Guinea

Use of convalescent plasma therapy in SARS patients in Hong Kong

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

A study in scarlet-convalescent plasma for severe influenza

The use of hyperimmune serum for severe influenza infections

Treatment with convalescent plasma for influenza A (H5N1) infection

Characteristics and outcome of mechanically ventilated patients with 2009 H1N1 influenza in Bosnia and Herzegovina and Serbia: impact of newly established multidisciplinary intensive care units

Severe H1N1-associated acute respiratory failure in immunocompromised children

Anti-Ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with Ebola virus disease

The use of Lassa fever convalescent plasma in Nigeria

Convalescent whole blood, plasma and serum in the prophylaxis of measles

Ribavirin, human convalescent plasma and anti-beta3 integrin antibody inhibit infection by Sin Nombre virus in the deer mouse model

Treatment of MERS-CoV: information for clinicians

Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia

Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Interim guidance for national health authorities and blood transfusion services. Geneva: World Health Organization

Convalescent plasma: new evidence for an old therapeutic tool?

Treatment of severe acute respiratory syndrome with convalescent plasma

Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma

Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

Convalescent plasma treatment reduced mortality in patients with severe pandemic Influenza A (H1N1) 2009 virus infection

Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study

Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial

The efficacy of convalescent plasma for the treatment of severe influenza. medRxiv

Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee

The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv, preprint

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory metaanalysis

Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease

Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice

The authors have disclosed no conflicts of interest.

